EGFR-TKIs have been proven to improve the survival of certain advanced NSCLC patients (28–30), with the overall benefit being determined primarily by the EGFR mutation subgroup (9–11,16,17,31). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.